Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H27NO4 |
| Molecular Weight | 333.422 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C[C@H]3N(C)CC[C@@]4(C[C@H](O)CC[C@@]34O)C2=C1OC
InChI
InChIKey=LCAHPIFLPICNRW-SVYNMNNPSA-N
InChI=1S/C19H27NO4/c1-20-9-8-18-11-13(21)6-7-19(18,22)15(20)10-12-4-5-14(23-2)17(24-3)16(12)18/h4-5,13,15,21-22H,6-11H2,1-3H3/t13-,15-,18-,19-/m1/s1
| Molecular Formula | C19H27NO4 |
| Molecular Weight | 333.422 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/405065Curator's Comment: description was created based on several sources, including, http://rusnewsjournal.com/4/522081/
Sources: http://www.ncbi.nlm.nih.gov/pubmed/405065
Curator's Comment: description was created based on several sources, including, http://rusnewsjournal.com/4/522081/
Drotebanol is an opioid drug developed in Japan and used for the treatment of cough under the name Metebanyl, although it is now no longer used. Drotebanol possess CNS activity and is considered to be narcotic in many countries.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5462594
Curator's Comment: Now is the part of Daiichi Sankyo.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/405065 |
Primary | METEBANYL Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of the centrally acting antitussives on ascites tumor cells. | 1983-04 |
|
| [Pharmacological studies on the cough-like reflex induced by chemical stimulation (author's transl)]. | 1978-04 |
|
| Dependence potential of drotebanol, codeine and thebaine tested in rhesus monkeys. | 1977-01-01 |
|
| [Pharmacological studies on the cough reflex]. | 1975-03 |
|
| [Absorption, distribution, excretion and metabolism of 14-hydroxydihydro-6-beta-thebainol 4-methylether (oxymethebanol)]. | 1970-01 |
|
| Pharmacological studies on a new specifically potent antitussive agent, 14-hydroxydihydro-6 beta-thebainol-4-methylether (oxymethebanol). | 1970-01 |
|
| [Pharmacological studies of a new potent antitussive agent, 14-hydroxy-dihydro-6 beta-thebainol-4-methyl ether (oxymethebanol)]. | 1969-03-20 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/405065
Oral doses of 4 mg/person
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 06:52:43 GMT 2025
by
admin
on
Wed Apr 02 06:52:43 GMT 2025
|
| Record UNII |
7RS2Q8MCK8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
||
|
DEA NO. |
9335
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB06416MIG
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
2958
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
DB01547
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
DROTEBANOL
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
C80575
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
DTXSID301017908
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104603
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
m1126
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
3176-03-2
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
3168
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
C001387
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
5463863
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
100000090360
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY | |||
|
7RS2Q8MCK8
Created by
admin on Wed Apr 02 06:52:43 GMT 2025 , Edited by admin on Wed Apr 02 06:52:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |